Mebhydrolin napadisylate. A possible cause of reversible agranulocytosis and neutropenia.
Mebhydrolin napadisylate is an antihistamine marketed in Australia as Fabahistin, and as an ingredient of Fabahistin Plus. Since June, 1973, 11 Australian reports associating this drug with either agranulocytosis or neutropenia have been received by the Adverse Drug Reactions Advisory Committee. In seven of these reports, mebhydrolin napadisylate was the only suspected drug. These reactions are probably uncommon, but the association should be borne in mind if evidence of agranulocytosis or neutropenia is found in patients taking the drug.
D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced* / Q000453:epidemiology; D001315:Australia; D002243:Carbolines / Q000009:adverse effects*; D005260:Female; D006634:Histamine H1 Antagonists / Q000009:adverse effects*; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000453:epidemiology
D002243:Carbolines; D006634:Histamine H1 Antagonists; D007211:Indoles; C025079:diazoline